Trials / Completed
CompletedNCT04693884
Cannabis Inhalation: Effects on Cardiovascular Function During Rest and Exercise
The Influence of Cannabis Inhalation During Exercise on Cardiovascular Health and Function: Exploring the Optimal Balance of Cannabinoids and Mode of Administration to Decrease Risk and Maximize Benefits
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Jamie Burr · Academic / Other
- Sex
- All
- Age
- 19 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This two-phase project seeks to examine the cardiovascular response to consumption of cannabis variants of different cannabinoid composition through different methods (smoking vs. vaporizing), at rest and during aerobic exercise. Multiple measures that have been shown to predict risk factors for chronic-disease and negative health outcomes will be assessed following cannabis consumption at rest or in combination with exercise. These techniques will examine arterial stiffness, vascular function, and cardiac function. In phase I and II, subjects will visit the lab on 6 different occasions; with 1 visit acting as an introductory visit, 1 as an exercise control visit, 2 as resting cannabis visits, and 2 as cannabis + exercise visits. Cannabis used in phase I of this study will consist of approximately 10% THC. On all visits, pulse wave velocity, flow mediated dilation, and echocardiography measures will be performed following cannabis consumption by smoking or vaporizing, and cannabis consumption by smoking or vaporizing followed by 20 minutes of exercise on a cycle ergometer. Phase II of the study will implore a similar design. In favor of altering method of consumption, in all visits cannabis will be consumed by vaporization and will be either a high cannabidiol (CBD: (\~10%)) and low delta-9-tetrahydrocannabinol (THC: (\<1%)), or a high THC (\~10%) and low CBD (\<1%) variant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cannabis | Cannabis of (\~10% THC concentration \<1% CBD concentration) will be smoked. |
| DRUG | Cannabis | Cannabis of (\~10% THC concentration \<1% CBD concentration) will be vaporized. |
| DRUG | Cannabis | Cannabis of (\~10% CBD concentration \<1% THC concentration) will be smoked. |
| DRUG | Cannabis | Cannabis of (\~10% CBD concentration \<1% THC concentration) will be vaporized. |
Timeline
- Start date
- 2021-09-01
- Primary completion
- 2025-04-16
- Completion
- 2025-04-16
- First posted
- 2021-01-05
- Last updated
- 2025-04-18
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT04693884. Inclusion in this directory is not an endorsement.